Predictors of optimal virological response to potent antiretroviral therapy

AIDS

Volumn 13, Issue 14, 1999, Pages 1873-1880

  Powderly, William G ^a   Saag, Michael S ^b   Chapman, Sharon ^c   Yu, George ^c   Quart, Barry ^c   Clendeninn, Neil J ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

Nelfinavir; Protease inhibitors; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CLINICAL TRIALS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HUMANS; LAMIVUDINE; MALE; NELFINAVIR; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; VIRAL LOAD; ZIDOVUDINE;

EID: 0032750441     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199910010-00009     Document Type: Article

References (19)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
3. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998, 351:543-549.
4. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280:78-86.
5. Report of the NIH Panel To Define Principles of Therapy of HIV Infection. Ann Intern Med 1998, 128:1057-1078.
6. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 1998, 280:35-41.
7. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med 1998, 339:1261-1268.
8. Pialoux G, Raffi F, Brun-Vezinet F, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med 1998, 339:1269-1276.
9. Staszewski S, Miller V, Sabin C, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 1999, 13:367-373.
10. Mehta S, Moore RD, Graham NM. Potential factors affecting adherence with HIV therapy. AIDS 1997, 11:1665-1670.
11. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998, 279:1977-1983.
12. Gross AJ, Clark VA. Survival Distributions: Reliability Application in the Biomedical Sciences. New York: John Wiley & Sons; 1977.
13. SAS Institute. SAS/STAT Users Guide, Version 6, 4th Edn. Carey, NC: SAS Institute; 1990.
14. Pithavala YK, Zhang M, Knowles M, Daniels R., Anderson R, Kerr B. Virologic response-plasma drug concentration relationship in a phase III Study of nelfinavir mesylate. XII International Conference on AIDS. Geneva June 1998 [abstract 12304].
15. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.
16. Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998, 128:906-911.
17. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society - USA Panel. JAMA 1998, 279:1984-1991.
18. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998, 12:F9-F14.
19. Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998, 12:1619-1624.